Nodetrip (previously Xeristar) (duloxetine)
- Region
- 🇪🇺 EU
- Active substance
- duloxetine
- Company
- Esteve Pharmaceuticals, S.A.
- Status
- Withdrawn
- Therapeutic area
- Anxiety Disorders; Depressive Disorder, Major; Diabetic Neuropathies
- CHMP opinion
- Thu 16 Sep 2004
- EU approval
- Fri 17 Dec 2004
- Application
- EMEA/H/C/000573
- ATC
- N06AX21
- Official record
- www.ema.europa.eu
Indication
Treatment of major depressive disorder; Treatment of diabetic peripheral neuropathic pain; Treatment of generalised anxiety disorder; Xeristar is indicated in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Duloxetine Viatris (previously Duloxetine Mylan) Authorised · Viatris Limited
- 🇺🇸 Duloxetine Hydrochloride Approved · Almatica
- 🇪🇺 Duloxetine Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Duloxetine Lilly Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Cymbalta Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Yentreve Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Ariclaim Withdrawn · Eli Lilly Nederland B.V.
- 🇪🇺 Duloxetine Sandoz Application withdrawn · Sandoz GmbH
- 🇪🇺 Duloxetine Boehringer Ingelheim Withdrawn · Boehringer Ingelheim International GmbH
Follow Nodetrip (previously Xeristar)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.